VALN News and Press, Valneva SE From 02/25/22

Valneva (NASDAQ:VALN) received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001. The company said that it is confident that it will be able to respond to the questions by the EMA's Committee for Medicinal P...

Reporting new Phase 2 data for their Lyme disease vaccine candidate, VLA15, Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) said on Friday that the companies have decided to move forward a three-dose series vaccination schedule in a future Phase 3 trial. Pfizer (PFE) and Valneva (VALN) have teste...

Valneva press release (NASDAQ:VALN): FY Revenue of €348.1M (+215.6% Y/Y). €253.3M of COVID-related revenues under the terminated U.K. agreement. €94.8M of product and other revenues (excluding COVID), at the higher end of previous guidance of €85M to...

Here Are 5 Biotech Stocks To Check Out In The Stock Market Today As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, a...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaccine companies are all the rage as giants like Moderna (NASDAQ: MRNA ) and Pfizer (NYSE: PFE ) race to develop a vaccine for the omicron variant. While daily U.S. cases of Covid-19 are still elevated, the num...

Biological E. Limited has won the Indian regulatory approval for CORBEVAX, a protein subunit COVID-19 vaccine designed to use the CpG 1018 adjuvant of the Dynavax Technologies (NASDAQ:DVAX). Dynavax (DVAX) shares have added ~1.5% in the pre-market. Developed by Biological E. in part...

Announcing topline results from its lot-to-lot trial for single-shot chikungunya vaccine candidate, VLA1553, Valneva (NASDAQ:VALN) said that the Phase 3 study met its primary endpoint. Results suggest that the three consecutively manufactured vaccine lots generated equivalent immune responses...

French drugmaker Valneva (NASDAQ: VALN) has high hopes for its COVID-19 vaccine candidate VLA2001. But recent data shows that VLA2001 performed dismally as a booster shot for individuals who received two doses of Pfizer 's (NYSE: PFE) and BioNTech 's (NASDAQ: BNTX) v...

5 Biotech Stocks To Check Out Before The End Of 2021 With the coronavirus pandemic kicking back into full swing, biotech stocks are once again at the forefront. For one thing, this part of the stock market today has and continues to work towards dealing with the pandemic. Now, as th...

Pressure on tech stocks led to broad losses on Wall Street Thursday, with the Nasdaq falling about 2.5%. The prospect of higher interest rates, signaled by the Federal Reserve's recent hawkish turn, pointed to lower tech valuations on the way. However, elsewhere in the market, a rising rate e...